B+
Bull case
25%
Probability
Target price
$12.75
Analysis reference price unavailable
Analysis 2025-12-07 · RankAlpha Sentiment AI
COGT
Cogent BiosciencesFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
50%
Probability
Target price
$8.50
Analysis reference price unavailable
Analysis 2025-12-07 · RankAlpha Sentiment AI
B-
Bear case
25%
Probability
Target price
$5.10
Analysis reference price unavailable
Analysis 2025-12-07 · RankAlpha Sentiment AI
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2025-12-07
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
0.0
Score
AI commentary
Market is event-driven and cautious: limited liquidity magnifies reactions to clinical or financing news. Investors are focused on upcoming readouts and runway; rumors of partnerships drive episodic volume. Overall sentiment is neutral-to-cautious—tilted toward the base case unless positive data or funding clarity arrives.
RankAlpha Sentiment AI - 2025-12-07
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
-eventUpcoming clinical data readout (early-stage program)High impact
Potential readout from an early clinical study could move valuation; timing uncertain — monitor company press releases/SEC filings for exact date [#10Qp12], [#PR-2025-06-01].
-eventRegulatory update or partnership announcementHigh impact
Biotech partnership or regulatory communication could materially re-rate shares; typical for small-cap biotechs [#PR-2024-11-15].
-catalystNegative trial result / clinical setbackHigh impact
Failed efficacy/safety readout would likely trigger sharp sell-off in biotech peers and this stock [#10Qp12].
Recommendation
N/A
No formal recommendation provided.
As of 2025-12-07 • Updated nightlySource: Internal modelMethodology